Edition:
United States

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

24.62CHF
23 Aug 2019
Change (% chg)

CHF0.20 (+0.82%)
Prev Close
CHF24.42
Open
CHF24.50
Day's High
CHF24.92
Day's Low
CHF24.30
Volume
417,732
Avg. Vol
327,770
52-wk High
CHF25.02
52-wk Low
CHF15.20

About

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including... (more)

Overall

Beta: --
Market Cap(Mil.): CHF2,796.17
Shares Outstanding(Mil.): 131.15
Dividend: --
Yield (%): --

Financials

  IDIA.S Industry Sector
P/E (TTM): -- 98.31 33.85
EPS (TTM): -3.51 -- --
ROI: -41.75 7.52 12.69
ROE: -88.68 7.94 17.13

BRIEF-Idorsia Says Janssen Reports Positive Top-Line Phase 3 Results For Ponesimod

* JANSSEN REPORTS POSITIVE TOP-LINE PHASE 3 RESULTS FOR PONESIMOD IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS

Jul 26 2019

BRIEF-Idorsia H1 US GAAP Net Loss At CHF 232 Mln

* UNCHANGED GUIDANCE FOR 2019: US GAAP OPERATING EXPENSES OF AROUND CHF 570 MILLION

Jul 23 2019

UPDATE 1-Idorsia confirms 2019 spending plan as clinical trials "on track"

ZURICH, April 18 Swiss biotech Idorsia said on Thursday that all four clinical trials of its late-stage drug hopefuls were "on track" as it confirmed expectations of spending 570 million Swiss francs ($564 million) in the current year on the projects.

Apr 18 2019

BRIEF-Idorsia Q1 US GAAP Net Loss Widens To CHF 106 Mln

* IDORSIA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2019

Apr 18 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates